Citigroup Inc. lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 98.6% during the second quarter, HoldingsChannel reports. The firm owned 25,202 shares of the company’s stock after acquiring an additional 12,515 shares during the quarter. Citigroup Inc.’s holdings in Amphastar Pharmaceuticals were worth $508,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the company. BlackRock Inc. raised its stake in Amphastar Pharmaceuticals by 3.3% in the 1st quarter. BlackRock Inc. now owns 7,377,178 shares of the company’s stock valued at $135,150,000 after acquiring an additional 233,012 shares during the period. Federated Hermes Inc. raised its position in shares of Amphastar Pharmaceuticals by 6.7% during the first quarter. Federated Hermes Inc. now owns 3,441,367 shares of the company’s stock worth $63,046,000 after acquiring an additional 215,484 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Amphastar Pharmaceuticals by 30.0% during the first quarter. Goldman Sachs Group Inc. now owns 718,882 shares of the company’s stock worth $13,170,000 after purchasing an additional 166,002 shares during the period. Geode Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 15.0% in the first quarter. Geode Capital Management LLC now owns 660,413 shares of the company’s stock valued at $12,098,000 after acquiring an additional 86,269 shares during the period. Finally, Morgan Stanley grew its stake in Amphastar Pharmaceuticals by 2.9% in the first quarter. Morgan Stanley now owns 341,600 shares of the company’s stock valued at $6,258,000 after acquiring an additional 9,692 shares during the period. Institutional investors own 56.53% of the company’s stock.
AMPH has been the topic of several analyst reports. TheStreet cut Amphastar Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Wednesday, September 15th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday. Finally, Northland Securities reiterated a “buy” rating and set a $23.00 price target on shares of Amphastar Pharmaceuticals in a report on Tuesday, July 20th.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Sunday, August 8th. The company reported $0.21 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.21. The business had revenue of $101.66 million for the quarter, compared to analyst estimates of $101.38 million. Amphastar Pharmaceuticals had a return on equity of 8.01% and a net margin of 2.72%. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 0.79 EPS for the current fiscal year.
In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 5,187 shares of the business’s stock in a transaction on Tuesday, July 20th. The stock was sold at an average price of $20.57, for a total value of $106,696.59. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 28.40% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.
Further Reading: How Does the Quiet Period Work?
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.